@article{11ff0d641b474912893bd64588d4b406,
title = "Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study",
abstract = "Objective: Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula. Method: Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Results: The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk decreased in patients treated with perphenazine, - 0.5% (SE 0.3), risperidone, - 0.6% (SE 0.3), and ziprasidone - 0.6% (SE 0.4). The difference in 10-year CHD risk between olanzapine and risperidone was statistically significant (p = 0.004). Differences in estimated 10-year CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL cholesterol levels differed between treatments. Conclusions: These results indicate that the impact on 10-year CHD risk differs significantly between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the agents studied in CATIE.",
keywords = "Antipsychotic, Blood pressure, Cholesterol, Coronary heart disease risk, Schizophrenia",
author = "Daumit, {Gail L.} and Goff, {Donald C.} and Meyer, {Jonathan M.} and Davis, {Vicki G.} and Nasrallah, {Henry A.} and McEvoy, {Joseph Patrick} and Robert Rosenheck and Davis, {Sonia M.} and Hsiao, {John K.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
note = "Funding Information: Dr. Rosenheck reports having received research funding from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, and Eli Lilly and Co.; and consulting fees from Bristol-Myers Squibb, Eli Lilly and Co., and Janssen Pharmaceutica Products. Dr. Lieberman reports having served as a consultant and/or advisor for Acadia, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, and Pfizer He does not receive financial compensation or salary support for his participation as a consultant or as a member of an advisory board. He has received grant support from Acadia, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, Merck, Organon, and Pfizer. He holds a patent from Repligen. Dr. McEvoy reports having received research funding from AstraZeneca, Forest Research Institute, Eli Lilly and Co., Janssen Pharmaeutica, and Pfizer Inc.; consulting or advisory board fees from Pfizer Inc. and Bristol-Myers Squibb; and lecture fees from Janssen Pharmaceutica, and Bristol-Myers Squibb. Dr. Meyer reports having received research support from Bristol-Myers Squibb and Pfizer, Inc., and has received speaking or advising fees from Bristol-Myers Squibb, Janssen Pharmaceutica, Pfizer, Inc., and Wyeth. Dr. Sonia Davis reports that she is an employee of Quintiles, Inc. Dr. Stroup reports he has consulted or received payment for speaking at events for AstraZeneca, Janssen, Lilly, Pfizer and Solvay. Dr. Nasrallah has received grants/research support from AstraZeneca, GSK, Jannsen, Lilly, Pfizer and Sanofi; has been a consultant, an advisory board member and served on the speakers' bureau for Abbott, AstraZeneca, Janssen, Pfizer and Shire. Dr. Goff has received grants/research support from Pfizer, Cephalon and Janssen, has received consulting, advisory board or lecture fees from Dainippon Sumitomo, Solvay/Wyeth, BristolMyerSquibb, Organon, Vanda and Eli Lilly. Dr. Daumit, Dr. Davis and Dr. Hsiao have no competing interests. Funding Information: The CATIE Schizophrenia Trial was supported by National Institute of Mental Health, Grant No. 1MH900001. The NIMH and study principal investigators are responsible for the design and conduct of the trial, and the primary analyses. There is no industry involvement in these activities. ",
year = "2008",
month = oct,
doi = "10.1016/j.schres.2008.07.006",
language = "English (US)",
volume = "105",
pages = "175--187",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",
}
